150 related articles for article (PubMed ID: 38258345)
1. Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations.
Yang X; Wang Y; Liang Z; Cui T; Chen D; Li G; Xu H; Liu S; Zhong N; Huang W; Wang Z
J Med Virol; 2024 Jan; 96(1):e29417. PubMed ID: 38258345
[TBL] [Abstract][Full Text] [Related]
2. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
Faraone JN; Qu P; Goodarzi N; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Jones D; Gumina RJ; Liu SL
Emerg Microbes Infect; 2023 Dec; 12(2):2270069. PubMed ID: 37819267
[TBL] [Abstract][Full Text] [Related]
3. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
[TBL] [Abstract][Full Text] [Related]
5. Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection.
Yang J; Hong W; Lei H; He C; Lei W; Zhou Y; Zhao T; Alu A; Ma X; Li J; Yang L; Wang Z; Wang W; Lu G; Shen G; Lu S; Wu G; Shi H; Wei X
Signal Transduct Target Ther; 2023 Jun; 8(1):252. PubMed ID: 37336889
[TBL] [Abstract][Full Text] [Related]
6. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
Lasrado N; Collier AY; Hachmann NP; Miller J; Rowe M; Schonberg ED; Rodrigues SL; LaPiana A; Patio RC; Anand T; Fisher J; Mazurek CR; Guan R; Wagh K; Theiler J; Korber BT; Barouch DH
Vaccine; 2023 Nov; 41(47):6904-6909. PubMed ID: 37872011
[TBL] [Abstract][Full Text] [Related]
7. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster.
Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J
Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825
[TBL] [Abstract][Full Text] [Related]
9. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
[TBL] [Abstract][Full Text] [Related]
10. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
[TBL] [Abstract][Full Text] [Related]
11. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.
Faraone JN; Wang X; Qu P; Zheng YM; Vincent E; Xu H; Liu SL
J Med Virol; 2024 Mar; 96(3):e29520. PubMed ID: 38528837
[TBL] [Abstract][Full Text] [Related]
13. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
[TBL] [Abstract][Full Text] [Related]
14. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Bolland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
Nat Commun; 2024 Mar; 15(1):2254. PubMed ID: 38480689
[TBL] [Abstract][Full Text] [Related]
15. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
[TBL] [Abstract][Full Text] [Related]
16. Continued evasion of neutralizing antibody response by Omicron XBB.1.16.
Faraone JN; Qu P; Zheng YM; Carlin C; Jones D; Panchal AR; Saif LJ; Oltz EM; Gumina RJ; Liu SL
Cell Rep; 2023 Oct; 42(10):113193. PubMed ID: 37777967
[TBL] [Abstract][Full Text] [Related]
17. Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants.
Faraone JN; Qu P; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Gumina RJ; Liu SL
Cell Rep Med; 2023 May; 4(5):101049. PubMed ID: 37148877
[TBL] [Abstract][Full Text] [Related]
18. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1.
Liu S; Liang Z; Nie J; Gao WB; Li X; Zhang L; Yu Y; Wang Y; Huang W
Emerg Microbes Infect; 2023 Dec; 12(2):2225638. PubMed ID: 37313604
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo.
Uraki R; Kiso M; Iwatsuki-Horimoto K; Yamayoshi S; Ito M; Chiba S; Sakai-Tagawa Y; Imai M; Kashima Y; Koga M; Fuwa N; Okumura N; Hojo M; Iwamoto N; Kato H; Nakajima H; Ohmagari N; Yotsuyanagi H; Suzuki Y; Kawaoka Y
Cell Rep; 2023 Dec; 42(12):113580. PubMed ID: 38103202
[TBL] [Abstract][Full Text] [Related]
20. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
